Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Active not recruiting 3Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 36Breast Neoplasms 32Rectal Neoplasms 25Esophageal Neoplasms 21Uterine Cervical Neoplasms 20Head and Neck Neoplasms 20Central Nervous System Neoplasms 19Lung Neoplasms 18Prostatic Neoplasms 17Lymphoma 17Esophageal Squamous Cell Carcinoma 17Leukemia 16Glioblastoma 16Squamous Cell Carcinoma of Head and Neck 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Carcinoma, Hepatocellular 12Sarcoma 10Neuroblastoma 10Neoplasms 10Nasopharyngeal Carcinoma 10Brain Neoplasms 10Astrocytoma 10Colorectal Neoplasms 9Pancreatic Neoplasms 7Glioma 7Neoplasm Metastasis 6Nasopharyngeal Neoplasms 6Lymphoma, Non-Hodgkin 6Stomach Neoplasms 5Recurrence 5

Interventions

Doxorubicin 2lentiviral minigene vaccine of COVID-19 coronavirus 1irinotecan sucrosofate 1brostallicin 1Vinorelbine 1Trabectedin 1Temozolomide 1Radiotherapy 1Cyclophosphamide 1Biological Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Rhabdomyosarcoma × Radiotherapy × Clear all
NCT05708391 2023-02-01

Radiotherapy Combined With Realgar-Indigo Naturalis Formula (RIF) in the Treatment of Rhabdomyosarcoma(RMS) in Children

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Unknown
53 enrolled
Sarcoma

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡